[{"from": "human", "value": "What can you tell me about this molecule? [C][C][C][C@@H1][Branch1][Ring2][C][C][O][N][C][=N][C][=Branch2][Ring2][=N][=N][C][=Branch2][Ring2][#Branch1][=C][Ring1][=Branch1][C][C][=C][Branch2][Ring1][N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][N][Branch1][#Branch1][C][C][=Branch1][C][=O][O][C][C][Branch1][C][F][Branch1][C][F][F][O][C][C][N]"}, {"from": "gpt", "value": "The molecule is a synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity."}]